6533b7dcfe1ef96bd12732e1
RESEARCH PRODUCT
Treatment until progression: Data of the “on-treatment” population of the FIRE-3 (AIO KRK-0306) study.
Christian LerchenmuellerLudwig Fischer Von WeikersthalThomas KirchnerCarsten HielscherTobias HeintgesSebastian StintzingG. SeipeltFrank KullmannDominik Paul ModestChristoph KahlSalah-eddin Al-batranMarkus MoehlerSwantje HeldVolker HeinemannAlexander KianiThomas DeckerMartina StauchUrsula Vehling-kaiserWerner ScheithauerAndreas Jungsubject
OncologyCancer Researchmedicine.medical_specialtyeducation.field_of_studyBevacizumabCetuximabbusiness.industryPopulationmedicine.disease_causeSurgeryOncologyInternal medicineMulticenter trialFOLFIRIMedicineIn patientProgression-free survivalKRASbusinesseducationmedicine.drugdescription
3589 Background: The FIRE-3 study (AIO KRK-0306) was designed as a randomized multicenter trial to compare the efficacy of FOLFIRI plus cetuximab (cet) to FOLFIRI plus bevacizumab (bev) as first-line treatment in KRAS WT mCRC patients. FOLFIRI plus cet as first-line treatment of KRAS WT mCRC patients resulted in comparable overall response rates (ORR) and progression free survival (PFS) when compared to FOLFIRI plus bev. Overall survival (OS) was significantly longer in the FOLFIRI plus cet arm. Methods: In this exploratory analysis outcome parameters were calculated in dependence of progression during antibody treatment. As reported before by Saltz et al. (ASCO GI 2007) an “on study treatment” population was defined using all RAS wild-type pts that were treated until progression or death occurred. To exclude early progressing patients the analysis was also performed in patients with a PFS >6 months. Results: See Table. Conclusions: In general, patients progressing during 1st-line treatment had a shorter ...
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2015-05-20 | Journal of Clinical Oncology |